API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215861
https://www.globenewswire.com/news-release/2023/06/12/2686333/0/en/Helsinn-announces-publication-of-data-evaluating-impact-of-AKYNZEO-fosnetupitant-palonosetron-on-treatment-outcomes-and-healthcare-costs.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-introduces-medication-to-prevent-chemotherapy-induced-nausea/articleshow/97243641.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.globenewswire.com//news-release/2022/11/28/2562924/0/en/Farma-Mondo-Group-and-Helsinn-sign-exclusive-partnership-to-commercialize-AKYNZEO-in-the-Baltic-region.html
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-fosnetupitant-chloride-hydrochloride-and-palonosetron-hydrochloride-1655270132.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-aprepitant-azilsartan-bupivacaine-cladribine-elrombopag-fosnetupitant-fostamatinib-ivacaftor-and-sodium-thiosulfate-1655270821.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206916
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202951
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204615
https://www.helsinn.com/news-and-events/helsinn-group-and-italfarmaco-announce-oral-presentation-of-nepa-netupitant-and-palonosetron-data-at-esmo-virtual-congress-2020/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208789
http://www.pharmatimes.com/news/five_meds_recommended_in_final_2019_chmp_meeting_1320403
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204702
https://www.reuters.com/article/us-amerisourcebergn-settlement/amerisourcebergen-to-pay-625-million-in-us-civil-fraud-settlement-idUSKCN1MB3IT
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205648
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205870
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206396
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206416
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206801
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207005
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209287
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206416
https://www.pharmacompass.com/pdf/news/jiangsu-yew-pharmaceutical-co-ltd-fails-edqm-inspection-1537438043.pdf
https://health.economictimes.indiatimes.com/news/pharma/glenmark-expands-its-oncology-franchise-in-india-with-launch-of-helsinns-akynzeo/64939838
https://www.biospectrumasia.com/news/25/11263/glenmark-launches-helsinns-akynzeo-in-india.html
https://globenewswire.com/news-release/2018/06/28/1530972/0/en/Helsinn-Therapeutics-U-S-Inc-becomes-the-exclusive-distributor-of-ALOXI-palonosetron-HCI-in-the-U-S.html
https://globenewswire.com/news-release/2018/06/28/1530972/0/en/Helsinn-Therapeutics-U-S-Inc-becomes-the-exclusive-distributor-of-ALOXI-palonosetron-HCI-in-the-U-S.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204289
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204289
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205870
https://www.thepharmaletter.com/article/glenmark-gets-license-to-market-akynzeo-in-india
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090713
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-launches-generic-nausea-drug-in-us/articleshow/63464361.cms
https://www.businesswire.com/news/home/20180323005590/en/Teva-Announces-Launch-Generic-Version-ALOXI%C2%AE-United
https://www.biospectrumasia.com/news/25/10366/mundipharma-acquires-australias-tolmar-adds-eligard-to-its-portfolio.html
https://www.pharmacompass.com/pdf/news/lenalidomide-approved-and-3-more-treatments-for-cancer-1514436566.pdf
https://www.manufacturingchemist.com/news/article_page/Patent_battle_for_Aloxi_in_the_US/128833
http://www.financialexpress.com/industry/drl-gets-unfavourable-patent-ruling-in-us-court/554719/
http://www.biospectrumasia.com/biospectrum/news/224733/mundipharma-expands-oncology-portfolio
https://www.pharmacompass.com/pdf/news/teva-pharms-generic-palonosetron-hydrochloride-approved-in-us-1475925665.pdf
http://www.pharma-excipients.ch/2016/10/04/optimization-of-melt-in-mouth-tablets-of-palonosetron-hcl-using-32-full-factorial-design/
http://www.pharma-excipients.ch/2016/10/04/optimization-of-melt-in-mouth-tablets-of-palonosetron-hcl-using-32-full-factorial-design/
https://www.pharmacompass.com/pdf/news/exela-pharma-scs-llc-palonosetron-hydrochloride-approved-by-fda-1472292697.pdf
https://www.pharmacompass.com/pdf/news/accords-palonosetron-receives-market-authorisation-in-the-eu-for-nausea-and-vomiting-caused-by-chemotherapy-1465475521.pdf
https://www.pharmacompass.com/pdf/news/sandozs-generic-bimatoprost-approved-in-us-for-glaucoma-1461414807.pdf
http://www.pharmatimes.com/Article/16-04-03/Seven_new_therapies_jump_towards_EU_approval.aspx
http://www.prnewswire.com/news-releases/helsinn-and-eisai-announce-revised-us-collaboration-for-cinv-franchise-300238039.html